Article Text

Download PDFPDF

Protocol
Seeking diagnostic and prognostic biomarkers for childhood bacterial pneumonia in sub-Saharan Africa: study protocol for an observational study
  1. Clarissa Valim1,
  2. Yekin Ajauoi Olatunji2,
  3. Yasir Shitu Isa2,
  4. Rasheed Salaudeen2,
  5. Sarwar Golam2,
  6. Edward F Knol3,
  7. Sheriffo Kanyi4,
  8. Abdoulie Jammeh5,
  9. Quique Bassat6,7,
  10. Wilco de Jager3,8,
  11. Alejandro A Diaz9,10,
  12. Roger C Wiegand11,
  13. Julio Ramirez12,
  14. Marsha A Moses13,14,
  15. Umberto D’Alessandro15,16,
  16. Patricia L Hibberd17,
  17. Grant A Mackenzie2,18
  1. 1Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA
  2. 2Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia
  3. 3Center of Translational Immunology, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  4. 4Bansang Hospital, Bansang, The Gambia
  5. 5Basse Hospital, Basse, The Gambia
  6. 6Hospital Clínic, Universitat de Barcelona, ISGlobal, Barcelona, Spain
  7. 7Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
  8. 8Luminex Corp, Austin, Texas, USA
  9. 9Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
  10. 10Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
  11. 11Independent Researcher, Boston, Massachusetts, USA
  12. 12Division of Infectious Diseases, University of Louisville, Louisville, Kentucky, USA
  13. 13Vascular Biology Program, Children’s Hospital Boston, Boston, Massachusetts, USA
  14. 14Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
  15. 15Disease Elimination and Control, Medical Research Council Unit, Fajara, Gambia
  16. 16London School of Hygiene & Tropical Medicine, London, UK
  17. 17Boston University School of Public Health, Boston, Massachusetts, USA
  18. 18Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
  1. Correspondence to Dr Clarissa Valim; cvalim{at}bu.edu

Abstract

Introduction Clinically diagnosed pneumonia in children is a leading cause of paediatric hospitalisation and mortality. The aetiology is usually bacterial or viral, but malaria can cause a syndrome indistinguishable from clinical pneumonia. There is no method with high sensitivity to detect a bacterial infection in these patients and, as result, antibiotics are frequently overprescribed. Conversely, unrecognised concomitant bacterial infection in patients with malarial infections occur with omission of antibiotic therapy from patients with bacterial infections. Previously, we identified two combinations of blood proteins with 96% sensitivity and 86% specificity for detecting bacterial disease. The current project aimed to validate and improve these combinations by evaluating additional biomarkers in paediatric patients with clinical pneumonia. Our goal was to describe combinations of a limited number of proteins with high sensitivity and specificity for bacterial infection to be incorporated in future point-of-care tests. Furthermore, we seek to explore signatures to prognosticate clinical pneumonia.

Methods and analysis Patients (n=900) aged 2–59 months presenting with clinical pneumonia at two Gambian hospitals will be enrolled and classified according to criteria for definitive bacterial aetiology (based on microbiological tests and chest radiographs). We will measure proteins at admission using Luminex-based immunoassays in 90 children with definitive and 160 with probable bacterial aetiology, and 160 children classified according to the prognosis of their disease. Previously identified diagnostic signatures will be assessed through accuracy measures. Moreover, we will seek new diagnostic and prognostic signatures through machine learning methods, including support vector machine, penalised regression and classification trees.

Ethics and dissemination Ethics approval has been obtained from the Gambia Government/Medical Research Council Unit The Gambia Joint Ethics Committee (protocol 1616) and the institutional review board of Boston University Medical Centre (STUDY00000958). Study results will be disseminated to the staff of the study hospitals, in scientific seminars and meetings, and in publications.

Trial registration number H-38462.

  • respiratory infections
  • diagnostic microbiology
  • paediatric infectious disease & immunisation
  • paediatric thoracic medicine
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • PLH and GAM contributed equally.

  • Contributors The study concept and design were conceived by CV, GAM and PLH with contributions from EFK, WdJ, AAD, RCW, JR, MAM, UDA and QB. Acquisition of clinical data were defined by CV, GAM, PLH, YAO, YSI, RS, SG, SK and AJ. Acquisition of laboratory data was defined by CV, RS, EFK, WdJ, RCW, MAM and GAM. The analytical plan was conceived by CV. Participant enrolment and follow-up will be conducted by YAO and YSI under direct supervision of GAM and oversight from PLH, SK, AJ and QB. Sample processing and diagnostic laboratory assays will be supervised by RS and data management by SG. All on-the-ground operations in the Gambia will be directly supervised by GM and overseen by CV. QB will be one of the clinicians assigning participants to one of the probable diagnostic groups. The multiplex immunoassay to quantify proteins will be conducted by EFK with inputs from CV, WdJ, RCW, JR and MAM. Analysis will be performed by CV. CV prepared the first draft of the manuscript with inputs from GAM, PLH, YAO, YSI, RS and SG. CV, YAO, YAI, RS, SG, EFK, SK, AJ, QB, WDJ, AAD, RCW, JR, MAM, UDA, PLH and GAM provided edits, reviewed and approved the final version of the manuscript, providing substantial intellectual contributions.

  • Funding This study will be supported by the National Institutes of Health of the USA (R21AI140258) and will leverage resources from the project entitled ‘Will the Ongoing Use of a Two-Dose, Rather Than Three-Dose Schedule of Pneumococcal Conjugate Vaccine, Have Similar Impact in Rural Gambia’ study funded by the Joint Global Health Trials scheme (MRC UK, Welcome, UK AID, UK National Institute for Health Research) and the Bill and Melinda Gates Foundation.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.